Sanofi Wins Japan Approval for Wayrilz in Rare Blood Disease
PARIS, June 23, 2026 Sanofi has secured an important regulatory milestone after Japan’s Ministry of Health, Labour and Welfare...
Wayrilz
Advertisement
Sanofi’s Wayrilz Approved in the U.S. as First BTK Inhibitor for Immune Thrombocytopenia
Sanofi has secured U.S. FDA approval for Wayrilz (rilzabrutinib), marking the first Bruton’s tyrosine kinase (BTK) inhibitor approved for...
Advertisement
